Healthy Returns: FDA chief Marty Makary on compounded GLP-1s, vaccines and China

Core Insights - The FDA is planning to phase out petroleum-based synthetic dyes in food, indicating a shift towards safer food additives [1] - The FDA is addressing concerns over the mass compounding of GLP-1 drugs, particularly in relation to telehealth companies like Hims & Hers [4][6] - The FDA's recent decision to review Moderna's mRNA flu shot application reflects ongoing regulatory challenges and industry concerns about consistency [7][9] Group 1: FDA's Regulatory Actions - The FDA is serious about cracking down on unlawful mass compounding of GLP-1s, citing quality and safety concerns [4] - The agency plans to restrict GLP-1 ingredients in non-approved compounded drugs, emphasizing compliance with federal law [4] - FDA Commissioner Makary expressed hope that illegal mass compounding of GLP-1s could end by 2026, contingent on compliance from manufacturers [6] Group 2: Moderna's Flu Shot Application - The FDA has reversed its earlier decision and will review Moderna's application for an experimental mRNA flu shot, with a decision expected by August 5 [7] - Makary stated that the FDA's guidance to Moderna was clear regarding trial design, particularly for older adult participants [8] - Moderna has contested the FDA's requirements for trial comparators, arguing that they are inconsistent with prior communications [9] Group 3: U.S. Drug Development Landscape - Makary warned that the U.S. is falling behind China in early-stage drug development, highlighting the need for reforms to streamline clinical trial processes [10][11] - He identified key bottlenecks in the drug development process, including hospital contracting and ethics reviews, which hinder competitiveness [12] - The FDA is exploring partnerships with health systems and academic centers to expedite the pre-IND process, aiming to enhance domestic innovation [13]